Effect of Empagliflozin on Left Ventricular Volumes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).

Matthew M.Y. Lee,Katriona Brooksbank,Kirsty Wetherall,Kenneth Mangion,Giles Roditi,Ross T. Campbell,Colin Berry,Victor Chong,Liz Coyle,Kieran F. Docherty,John G. Dreisbach,Catherine Labinjoh,Ninian N. Lang,Vera Lennie,Alex McConnachie,Clare Murphy,Colin J. Petrie,John R. Petrie,Iain A. Speirits,Steven Sourbron,Paul Welsh,Rosemary Woodward,Aleksandra Radjenovic,Patrick B. Mark,John J.V. McMurray,Pardeep S. Jhund,Mark C. Petrie,Naveed Sattar

Effect of Empagliflozin on Left Ventricular Volumes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).

2020

Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with heart failure and reduced ejection fraction ...

Keywords:

in patient
Type 2 diabetes
Ejection fraction
Heart failure
Internal medicine
Cardiology
Prediabetes
cardiovascular death
Empagliflozin
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations